Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma
Drug‐induced pneumonitis is rare, and can result in death. Here, we present a report of a patient with adenocarcinoma harboring EGFR exon 19 deletion mutation treated with osimertinib as first‐line treatment. After six days of treatment, extremely early onset severe pneumonitis was diagnosed. Discon...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-09-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13565 |